thanks to the spin-off from LSI of the division’s standing in the future, under an independent Board and have a better control over the operational activities and costs, said Lonza today is Monday. The Segment remains to be 100% owned by Lonza. The process for separation had already been initiated and should be completed by mid-2020, it is called. LSI should rise with the spin-off of the world’s leading suppliers in the control of microorganisms.
removal of up to 130 Points
in Order to improve the efficiency, it is checked in addition, the reduction of approximately 130 positions, as it is called on. Of these, around 50 would be in Switzerland, and 35 in the United States. The program is limited to the Segment LSI and the corresponding support functions. In the pharmaceuticals Segment Biotech & Nutrition have no influence.
Lonza wants to minimize the reported job losses, and affected employees, where possible, other free position in the company or early retirement offer. (SDA)